戻る
「早戻しボタン」を押すと検索画面に戻ります。

今後説明を表示しない

[OK]

コーパス検索結果 (1語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 essness, along with nonmotor wearing off and akathisia.
2 ory, response inhibition, mood, anxiety, and akathisia.
3 loperidol decanoate was associated with more akathisia.
4 stonia, tremor, myoclonus, stereotypies, and akathisia.
5        Molindone led to more self-reports of akathisia.
6 ues and assessment of movement disorders and akathisia.
7  placebo, including depression, anxiety, and akathisia.
8 cantly larger increases in global ratings of akathisia (0.73 [95% CI, 0.59-0.87] vs 0.45 [95% CI, 0.3
9 emergent adverse event for brexpiprazole was akathisia (2 mg: 4.4%; 4 mg: 7.2%; placebo: 2.2%).
10 ; they also had significantly les observable akathisia (24% versus 53%) and significantly less severe
11 gent adverse events were somnolence (10.0%), akathisia (7.7%), and sedation (7.7%) in the open-label
12 epressive symptoms, baseline motor function, akathisia and dystonia during treatment, growth hormone
13 gnificantly greater reductions in tremor and akathisia and greater improvements in most items on the
14 uality of life, and its benefits in reducing akathisia and improving cognition must be balanced with
15 >/=10%) in cariprazine-treated patients were akathisia and insomnia; weight gain was slightly higher
16 erability concerns include the potential for akathisia and Parkinsonism.
17 se events and aripiprazole with more initial akathisia and, unexpectedly, more sedation.
18 ts with respect to measures of parkinsonism, akathisia, and dyskinesias.
19  dry mouth, increased appetite, weight gain, akathisia, and high alanine aminotransferase levels; tho
20  lurasidone were nausea, somnolence, tremor, akathisia, and insomnia.
21 tatic model of insulin resistance (HOMA-IR), akathisia, and sedation.
22 iated with lurasidone were nausea, headache, akathisia, and somnolence.
23 sitive symptoms, conceptual disorganization, akathisia, and tardive dyskinesia.
24 ide effects; 6) extrapyramidal side effects, akathisia, and tardive dyskinesia; 7) cataracts; and 8)
25 ment-aripiprazole group included somnolence, akathisia, and weight gain.
26  linked to several adverse events, including akathisia (aripiprazole), sedation (quetiapine, OFC, and
27  rate of treatment-emergent parkinsonism and akathisia but had significantly more weight gain, compar
28 idol group reported symptoms consistent with akathisia, compared with six (20%) patients in the zipra
29 om outcomes and measures of parkinsonism and akathisia did not differ between medications.
30 cularly with olanzapine), fatigue, sedation, akathisia (for aripiprazole), and extrapyramidal symptom
31 ette's syndrome, restless legs syndrome, and akathisia, have traditionally been considered to be diso
32       Olanzapine was associated with reduced akathisia in the intention-to-treat analysis (P<.001) an
33 hostility and the Simpson-Angus Rating Scale akathisia item.
34 ements in the Simpson-Angus scale and Barnes Akathisia Scale scores, while haloperidol-treated patien
35 amidal symptoms (Simpson-Angus Scale, Barnes Akathisia Scale, Abnormal Involuntary Movement Scale) we
36 Abnormal Involuntary Movements Scale, Barnes Akathisia Scale, and Modified Simpson-Angus [for Extrapy
37 ormal Involuntary Movement Scale, the Barnes Akathisia Scale, the Simpson-Angus Scale, and the Arizon
38 using the Simpson-Angus Scale and the Barnes Akathisia Scale; abnormal involuntary movements were ass
39 rkinsonian symptoms and quetiapine with less akathisia than haloperidol, aripiprazole, risperidone, a
40                  In addition to sedation and akathisia, the most common adverse events were tremor (4
41                             The incidence of akathisia was higher with 120 mg of lurasidone (22.9%) t
42                                              Akathisia was more common with aripiprazole at week 2 (o
43                                              Akathisia was the most common adverse effect of aripipra
44                  Extrapyramidal symptoms and akathisia were similar in the two groups, although no an
45 tment-emergent adverse events (eg, insomnia, akathisia, worsening of schizophrenia, headache, anxiety

WebLSDに未収録の専門用語(用法)は "新規対訳" から投稿できます。